FDA Finalizes Guidance Documents Aimed At Easing Post-Pandemic Regulatory Transitions

The documents describe the US agency’s preferred approach toward products cleared under EUAs or other alternate approaches during the COVID-19 public health emergency.

FDABldg1ExteriorWithCircle_1200x675

The US Food and Drug Administration eased up on labeling recommendations but kept a controversial 180-day compliance period in two newly finalized guidance documents aimed at easing the transition out of the COVID-19 public health emergency (PHE), which is set to end in May.

The documents recommend strategies for developing a transition implementation plan, completing a marketing submission, and other key tasks. One applies...

More from Regulation

More from Policy & Regulation